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EA
S  u  m  m  a  r  y
Carcinoembryonic  antigen  is a tumour  marker  commonly  increased  in gastrointestinal  and  pulmonary
cancers.  We  report  a case  of  a 46-year-old  man  with  a mucoepidermoid  carcinoma  of the  base  of  tongue
with  an elevated  and traceable  serum  carcinoembryonic  antigen  level.  This  antigen  proved  to  be  a valuable
marker  in the  treatment  follow-up.  When  a  raised  carcinoembryonic  antigen  level  is  found,  salivary  gland
malignancies  should  be  taken  into  the differential  diagnosis  and  clinical  examination  of the  head  and  neck
region  should  not  be  overlooked.
©  2014  Société  française  de  radiothérapie  oncologique  (SFRO).  Published  by Elsevier  Masson  SAS. All
rights reserved.
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r  é  s  u  m  é
L’antigène  carcinoembryonique  est un marqueur  tumoral  qui  est  généralement  augmenté  dans  les can-
cers  gastro-intestinaux  et pulmonaires.  Nous  rapportons  un  cas d’un  homme  de  46 ans  atteint  d’un  cancer
mucoépidermoïde  de  la  base  de  la  langue  avec  une  concentration  d’antigène  carcinoembryonique  élevéentigène carcinoembryonique
et trac¸ able.  L’antigène  carcinoembryonique  est  un  marqueur  à  surveiller  dans  le  suivi post-thérapeutique.
Lorsque  la  concentration  sérique  d’antigène  carcinoembryonique  augmente,  une  tumeur  des  glandes  sali-
vaires  doit  être évoquée  dans  le diagnostic  différentiel,  avec  un  examen  clinique  de  la sphère  des  voies
aérodigestives  supérieures.
©  2014  Société  française  de  radiothérapie  oncologique  (SFRO).  Publié  par  Elsevier Masson  SAS.  Tous. Introduction
The carcinoembryonic antigen is a well-known and used tumourPlease cite this article in press as: Vingerhoedt SI, et al. Elevated carc
cancer: A case report and literature study. Cancer Radiother (2014), h
arker especially in colorectal cancer [1].
We  present a case of elevated serum carcinoembryonic antigen
evel in a patient with a mucoepidermoid carcinoma. The assumed
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association between the presence of mucoepidermoid carcinoma
and a raised serum carcinoembryonic antigen level was studied.
We further give a short summary of the epidemiology, histological
grading and therapy of mucoepidermoid carcinomas.
2. Case reportinoembryonic antigen tumour marker caused by head and neck
ttp://dx.doi.org/10.1016/j.canrad.2014.09.008
A 46-year-old non-smoker without important medical history
presented in the winter of 2011 with complaints of pyroris. His
general practitioner performed a blood test, which showed an
lsevier Masson SAS. All rights reserved.
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Fig. 1. A, B. Axial and sagittal baseline CT showing a tumoural mass at the right base of tongue with extension into the right vallecula. C, D. Axial and sagittal CT at 4 months
after  the end of therapy showing no evidence for tumoural disease. Complete therapy response.
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t, B. Scanographies axiale et sagittale de référence montrant une masse tumorale à la 
agittale à 4 mois après la ﬁn du traitement ne montrant plus aucun signe de maladie t
ncreased serum carcinoembryonic antigen level up to 28.6 ng/mL.
he patient was referred to the gastroenterology outpatient clinic
t the University Hospitals Leuven. CT of the chest and abdomen
howed no evidence of malignancy. Esophagogastroduodenoscopy
nd biopsy indicated a Barrett esophagitis without dysplasia.
olonoscopy was  negative. Therapy with proton-pump inhibitors
as started. At that time no abnormality was noted in the upper
erodigestive tract.
During the summer of 2012, the patient experienced an uncom-
ortable feeling in his throat with complaints of odynophagia and
hanges in speech. Clinical examination was negative apart from
ndirect laryngoscopy revealing an abnormal mass at the base
f tongue. A CT study of the neck conﬁrmed a large tumoural
rocess (26 × 37 × 36 mm)  in the right base of the tongue with
xtension into the right vallecula (Fig. 1A and B). No suspect
ymph nodes were seen. A transoral biopsy revealed a low-grade
ucoepidermoid carcinoma. Further investigation for hematolog-Please cite this article in press as: Vingerhoedt SI, et al. Elevated carc
cancer: A case report and literature study. Cancer Radiother (2014), h
cal metastases by CT of the chest and ultrasound of the abdomen
roved negative, so the tumour was staged cT3N0M0. The serum
oncentration of carcinoembryonic antigen was elevated at that
ime to 41.5 ng/mL.roite de la langue avec extension dans la vallécule droite. C, D. Scanographies axiale et
le. Réponse complète à la thérapie.
In general, the preferred treatment for a low-grade mucoepider-
moid carcinoma of minor salivary gland origin is surgical removal,
if indicated combined with postoperative radiotherapy [2]. At this
site of origin however, a radical, non-mutilating, function preser-
ving resection is very hard to perform. Given the large volume
of the tumour at the base of the tongue (Fig. 1A and B) and
the imminent danger of upper airway obstruction, a combination
treatment approach consisting of maximal surgical debulking and
postoperative radiation was  chosen. For the debulking procedure,
a robot-assisted transoral resection (da Vinci surgical systems -
Intuitive Surgical Inc, Sunnyvale, California) was attempted. Due
to the nature of the obstruction, intubation was impossible and a
tracheostomy had to be performed. Even then satisfactory expo-
sure using the Larynx advanced retractor system (LARS, Fentex,
Tuttlingen, Germany) was  very difﬁcult given the combination
of a large tongue, a limited mouth opening and a normal denti-
tion in this patient. In this way, using the robotic system, onlyinoembryonic antigen tumour marker caused by head and neck
ttp://dx.doi.org/10.1016/j.canrad.2014.09.008
a partial resection was  feasible, and subsequently the remnant
tumour was resected further using a distensible laryngoscope (Karl
Storz, Tuttlingen, Germany) in combination with an Acublade® sys-
tem (Lumenis, Santa Clara, CA, USA) mounted on an operating
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Fig. 2. Immunohistochemical staining of a low-grade mucoepidermoid carcinoma,
using a monoclonal antibody against carcinoembryonic antigen (DAKO ready to use),
showing positive cytoplasmatic staining of the tumoural cells. Representative image
shown (×200).
Coloration immuno-histochimique d’un cancer mucoépidermoïde de la base de la langue
utilisant un anticorps monoclonal contre l’antigène carcinoembryonique (DAKO ready
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eo  use) révélant une coloration cytoplasmique positive des cellules tumorales. Une image
eprésentative est montrée (×200).
icroscope. Anatomopathological examination showed a low-
rade mucoepidermoid carcinoma resected in two  pieces, one with
 maximal diameter of 1.6 cm and one with a maximal diameter of
.0 cm,  but with positive lateral and deep section margins. There
as no lymphovascular or perineural invasion. Immunostaining
ith a monoclonal antibody against carcinoembryonic antigen was
ositive in the mucous cells (Fig. 2).
The postoperative carcinoembryonic antigen level fell to
.3 ng/mL. As planned, postoperative radiation therapy was  per-
ormed. A total dose of 66 Gy in 33 fractions of 2 Gy was given on
he initial tumour region using intensity-modulated radiotherapy
IMRT). Clinical evaluation 2 months after the end of the therapy,
howed complete clinical remission of the tumour with a nor-
alized carcinoembryonic antigen level of 1.2 ng/mL. Radiographic
ontrol was performed 4 months post-therapy and revealed a com-
lete therapy response (Fig. 1C–D). At last follow-up, 14 months
fter therapy, patient remained free of disease with a normal car-
inoembryonic antigen level (Fig. 3).
. Discussion
Salivary gland malignancies have an overall incidence in the
estern world of about 2.5 to 3.0 per 100,000 per year [3]. Accord-
ng to the EUROCARE - 4 studies published in 2007, 5741 new cases
f salivary gland cancer were diagnosed in Europe between 1995
nd 1999 with a mean ﬁve-years overall survival of 64.6% [4]. The
ost common type of salivary gland cancer is the mucoepidermoid
arcinoma [3,5]. Lung and breast are known as other organs where
ucoepidermoid carcinomas occur [6,7].
Roughly 10% to 15% of the salivary gland malignancies arise in
he minor salivary glands. Minor salivary glands are composed of
cini with a short ductal system and no capsule [8]. Between 450
nd 1000 minor salivary glands are widely spread in the upper
erodigestive tract, middle ear, nose, paranasal sinuses, pharynx
nd larynx. The majority (90%) is located in the oral cavity and
ropharynx [2].Please cite this article in press as: Vingerhoedt SI, et al. Elevated carc
cancer: A case report and literature study. Cancer Radiother (2014), h
Mucoepidermoid carcinoma is histologically classiﬁed into
hree grades: high-, intermediate- and low-grade tumours [9,10].
he tumours are composed of varying proportions of mucous,
pidermoid, intermediate, columnar and clear cells. There is a PRESS
thérapie xxx (2014) xxx–xxx 3
predilection for women and a broad age range with the highest
prevalence in the ﬁfth decade of life [11–14]. Intraoral minor sali-
vary gland mucoepidermoid carcinomas are primarily treated by
surgery [2,15–17]. Postoperative radiotherapy with a minimal total
dose of 60 Gy can be associated to increase local control [16–21].
Patients with unresectable tumours can be offered a treatment with
primary radiotherapy [16] with a total dose of > 66 Gy using 2 Gy per
fraction [22,23] or using accelerated hyperfractionation (1.6 Gy per
fraction) [24].
In this case, the carcinoembryonic antigen level proved to be
a sensitive tumour marker. Carcinoembryonic antigen is a gly-
coprotein, which is involved in cell adhesion. It is an oncofetal
antigen that is normally produced in gastrointestinal tissue only
during fetal development. In adulthood, carcinoembryonic anti-
gen can be abnormally elevated in the serum of cancer patients,
especially in adenocarcinomas as those arising in the colon, lung,
breast, etc. [25]. The use of carcinoembryonic antigen as a tumour
marker is most commonly known in colorectal cancer. Because it
lacks sensitivity, serum carcinoembryonic antigen is not a use-
ful population-screening tool for colorectal cancer. However, in
patients with established disease, the level of the serum carcinoem-
bryonic antigen correlates with disease load, therapy response and
prognosis [1]. In salivary gland cancers, the value of carcinoembry-
onic antigen as a tumour marker has rarely been reported.
In an immunohistochemical study of 1986, Takahashi et al. sug-
gested that the presence of carcinoembryonic antigen could be
used as a marker to differentiate between benign and malign areas
of carcinoma in pleomorphic adenoma of the salivary gland. In
malignant salivary gland carcinomas, carcinoembryonic antigen
was abnormally and excessively localized in the cytoplasm of the
epithelial cells and in the luminal contents of neoplastic glands
[26]. In another immunohistochemical study of 2013, Schneider
et al. assessed the expression of 21 tumour antigens in 158 parotid
gland tumour samples to differentiate between benign and malign
salivary tumours. Positive immunostaining of carcinoembryonic
antigen was  seen in 67.6% of the malignant tumours and in 29%
of the benign tumours [27]. Two  following studies investigated the
expression of carcinoembryonic antigen in mucoepidermoid car-
cinoma s. A ﬁrst study of Lu et al. showed that carcinoembryonic
antigen was  negative in all normal salivary gland tissue and posi-
tive in 78.9% of the malignant tissue. The positive rates and staining
intensity of carcinoembryonic antigen in carcinoma tissue gradu-
ally decreased with the decline of tumour differentiation [28]. The
second study of da Cruz Perez et al. showed that 87.5% (14/16)
of mucoepidermoid carcinomas had positive immunostaining for
carcinoembryonic antigen [29]. These studies indicate that carci-
noembryonic antigen can be an important marker of malignancy in
salivary gland tumours, especially in mucoepidermoid carcinomas.
In 1996, Angelov et al. showed that the average concentra-
tion of carcinoembryonic antigen in patients with mucoepidermoid
carcinoma in serum (14.94 ng/mL) and in saliva (216.67 ng/mL)
was signiﬁcantly higher than in the healthy group and in the
pleomorphic adenoma group (P < 0.001). A correlation was found
between high serum concentrations and salivary secretions of
carcinoembryonic antigen, and a high immunohistochemical inten-
sity of carcinoembryonic antigen expression in the tumour tissue.
An increased synthesis and secretion of carcinoembryonic anti-
gen was determined by the prevalence of tubular structures, a
high proliferative activity in pleomorphic adenoma and its malig-
nant transformation [30,31]. He et al. had a similar experience in
2009, comparing the level of salivary and serum carcinoembryonic
antigen in 80 patients with oral minor salivary gland malignantinoembryonic antigen tumour marker caused by head and neck
ttp://dx.doi.org/10.1016/j.canrad.2014.09.008
tumours, to the level in 40 patients with benign tumours and in
80 healthy controls. Mean salivary carcinoembryonic antigen level
was signiﬁcantly higher in the malignant tumours (47.57 ng/mL)
than in the benign tumours (20.99 ng/mL) and the healthy group
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Fig. 3. Evolution of the level of carcinoembryonic antigen as a tumour marker in function of time and treatments. 12/12/2012: surgery; 16/01–01/03/2013: postoperative
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volution de la concentration d’antigène carcinoembryonique en fonction du temps et d
11.36 ng/mL) (P < 0.001). Serum carcinoembryonic antigen level
as increased in only 8.75% (7/80) of the malignant tumour cases
ith an average level of 9.16 ng/mL. This study reveals a better cor-
elation between the carcinoembryonic antigen level in saliva than
n serum in patients with oral minor salivary gland tumours, indi-
ating direct secretion of various proteins into the saliva. To detect
umour markers in saliva may  be of important clinical signiﬁcance
32].
Only two previous studies have reported the role of a raised
erum carcinoembryonic antigen level in survival and recurrence
f salivary gland tumours. Kuhel et al. reported a case of a patient
ith an adenoid cystic carcinoma of the trachea and elevated
erum carcinoembryonic antigen level, which declined after sur-
ical resection. The serum carcinoembryonic antigen level raised
gain when the patient developed abdominal metastases and then
ecreased after tumour debulking. Immunohistochemical study
f the tumour was positive for carcinoembryonic antigen [33].
nother case report of Noriyuki et al. presented a case of a 38-year-
ld woman with a low-grade mucoepidermoid carcinoma of the
ight upper lung with an elevated serum carcinoembryonic antigen
evel (12.4 ng/mL). Positive immunostaining of carcinoembryonic
ntigen was seen in 45% of the tumour cells. Postoperatively,
he carcinoembryonic antigen level normalized. At last follow-up,
7 months after therapy, patient had no evidence of recurrence
ith a normal serum carcinoembryonic antigen level [34].
. Conclusions
In this case report an elevated carcinoembryonic antigen level
ed to several technological exams, looking for a primary gas-
rointestinal tumour. During follow-up, a salivary gland tumour
as diagnosed. After treatment of this tumour and during further
ollow-up, carcinoembryonic antigen level proved to be a use-
ul tumour marker. Positive immunostaining of the salivary gland
umour followed by the normalization of the serum carcinoem-
ryonic antigen level after treatment, pinpointed it as a reliable
umour marker reﬂecting tumourload. In line with these ﬁndings,
everal other studies and case reports in the literature also suggest
his possible role for the measurement of serum and salivary car-
inoembryonic antigen levels following the immunohistochemicalPlease cite this article in press as: Vingerhoedt SI, et al. Elevated carc
cancer: A case report and literature study. Cancer Radiother (2014), h
onﬁrmation of its expression in malignant salivary gland tumour
issue.
Whereas a raised carcinoembryonic antigen level classically
eads to the investigation of colorectal and lung cancer, salivary
[
[tements.
gland malignancies should be taken into the differential diagnosis
and clinical examination of the head and neck region should not be
overlooked.
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